Faster Science, Better Drugs

In this feed drop from the Internet History Podcast, host Brian McCullough speaks with Chris Dixon, general partner at a16z, about his path from 1980s hobbyist programmer to one of the most prominent venture capitalists in tech. Chris traces his career from quantitative finance t ...  Show more

Erik Torenberg, Ben Horowitz, and Marc Andreessen discuss how the media landscape has fundamentally changed and what a16z is doing about it. They cover why offense beats defense, why individuals now matter more than corporate brands, why speed wins in the new media landscape, and ...  Show more

On this week’s episode of No Priors, Sarah Guo is joined by leading members of the teams at Vevo Therapeutics and the Arc Institute – Nima Alidoust, CEO/Co-Founder at Vevo Therapeutics; Johnny Yu, CSO/Co-Founder at Vevo Therapeutics; Patrick Hsu, CEO/Co-Founder at Arc Institute; ...  Show more

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ...  Show more

Cancer care in the U.S. costs over $250 billion each year, and nearly 2 million Americans receive a new diagnosis annually, yet too often the journey begins with silence: no call, no plan, no guide.

In this episode, a16z’s Vineeta Agarwala and Jay Rughani talk with Thyme ...

Jacob Kimmel thinks he can find the transcription factors to reverse aging. We do a deep dive on why this might be plausible and why evolution hasn’t optimized for longevity. We also talk about why drug discovery has been getting exponentially harder, and what a new platform for ...  Show more